Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more...
Myeloma NZ
Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Myeloma Australia's Medical and Scientific Advisory Group (MSAG)Â presents the article of the week. Multiple myeloma (MM) is the third most common...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or...
Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively...
COVID-19’s Impact on How Patients with CLL, Myeloma Have Received Treatment
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from...
Newsletter: Autumn 2020
Hello Everybody I hope that you are all coping with the lock-down as best that you can. It’s been a difficult time for many people and especially...
Blood cancer patients at most risk from COVID-19 compared to other cancers
Patients with haematological cancers are at higher risk of COVID-19 infection and experience more severe disease compared to people with other...
Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its...
Genetic Test Could Determine Patients With Ultra High Risk Multiple Myeloma
A new study published in Leukemia revealed that researchers at the Institute of Cancer Research in London have found a new genetic test that could...
First case of COVID-19 in a patient with multiple myeloma
The immunosuppressant tocilizumab may be a promising option for myeloma patients with COVID-19, a case study from China suggests. Dr Changcheng...
Genetic Test Identifies Ultra-High-Risk Myeloma Patients
A new test can identify patients with multiple myeloma (MM) who have a high-risk genetic profile as well as multiple chromosomal abnormalities. In...
WEBINAR: Leading experts to give their views on treating multiple myeloma patients during the COVID-19 pandemic
The COVID-19 pandemic continues to put a strain on healthcare delivery around the world. In this environment, haematologists are adapting their...